Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis

Human Molecular Genetics

Volumn 22, Issue 9, 2013, Pages 1735-1745

  Dreidax, Daniel ^a   Gogolin, Sina ^a   Schroeder, Christina ^a   Muth, Daniel ^a   Brueckner, Lena Marie ^a   Hess, Elisa Maria ^a   Zapatka, Marc ^a   Theißen, Jessica ^b   Fischer, Matthias ^b   Ehemann, Volker ^c   Schwab, Manfred ^a   Savelyeva, Larissa ^a   Westermann, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE G1 PHASE; CELL GROWTH; CELL VIABILITY; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 9; CHROMOSOME 9P; CLONOGENESIS; COLONY FORMATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPIGENETIC REPRESSION; FLUORESCENCE IN SITU HYBRIDIZATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE LOCATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; DRUG ANTAGONISM; FEMALE; GENE DELETION; GENE EXPRESSION; GENETICS; HETEROZYGOSITY LOSS; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPIGENETIC REPRESSION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE DELETION; GENE EXPRESSION; HISTONES; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEUROBLASTOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875929766     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt020     Document Type: Article

References (55)

1. Olivier, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C. and Hainaut, P. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat., 19, 607-614.
2. Vousden, K.H. and Lu, X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
3. Castleberry, R.P. (1997) Neuroblastoma. Eur. J. Cancer, 33, 1430-1437.
4. Tweddle, D.A., Pearson, A.D., Haber, M., Norris, M.D., Xue, C., Flemming, C. and Lunec, J. (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett., 197, 93-98.
5. Westermann, F., Muth, D., Benner, A., Bauer, T., Henrich, K.O., Oberthuer, A., Brors, B., Beissbarth, T., Vandesompele, J., Pattyn, F. et al. (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol., 9, R150.
6. Carr-Wilkinson, J., O'Toole, K., Wood, K.M., Challen, C.C., Baker, A.G., Board, J.R., Evans, L., Cole, M., Cheung, N.K., Boos, J. et al. (2010) High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin. Cancer Res., 16, 1108-1118.
7. Van Maerken, T., Speleman, F., Vermeulen, J., Lambertz, I., De Clercq, S., De Smet, E., Yigit, N., Coppens, V., Philippe, J., De Paepe, A. et al. (2006) Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res., 66, 9646-9655.
8. Honda, R. and Yasuda, H. (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J., 18, 22-27.
9. Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F. and Sherr, C.J. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA, 95, 8292-8297.
10. Llanos, S., Clark, P.A., Rowe, J. and Peters, G. (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat. Cell. Biol., 3, 445-452.
11. Midgley, C.A., Desterro, J.M., Saville, M.K., Howard, S., Sparks, A., Hay, R.T. and Lane, D.P. (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene, 19, 2312-2323.
12. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W. et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92, 713-723.
13. Stott, F.J., Bates, S., James, M.C., McConnell, B.B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K.H. et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17, 5001-5014.
14. Zhang, Y., Xiong, Y. and Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725-734.
15. Sharpless, N.E. (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res., 576, 22-38.
16. Bignell, G.R., Greenman, C.D., Davies, H., Butler, A.P., Edkins, S., Andrews, J.M., Buck, G., Chen, L., Beare, D., Latimer, C. et al. (2010) Signatures of mutation and selection in the cancer genome. Nature, 463, 893-898.
17. Thompson, P.M., Maris, J.M., Hogarty, M.D., Seeger, R.C., Reynolds, C.P., Brodeur, G.M. and White, P.S. (2001) Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res., 61, 679-686.
18. Carr, J., Bell, E., Pearson, A.D., Kees, U.R., Beris, H., Lunec, J. and Tweddle, D.A. (2006) Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res., 66, 2138-2145.
19. Beltinger, C.P., White, P.S., Sulman, E.P., Maris, J.M. and Brodeur, G.M. (1995) No CDKN2 mutations in neuroblastomas. Cancer Res., 55, 2053-2055.
20. Diccianni, M.B., Chau, L.S., Batova, A., Vu, T.Q. and Yu, A.L. (1996) The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Cancer Lett., 104, 183-192.
21. Iolascon, A., Giordani, L., Moretti, A., Tonini, G.P., Lo Cunsolo, C., Mastropietro, S., Borriello, A. and Ragione, F.D. (1998) Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma. Pediatr. Res., 43, 139-144.
22. Marshall, B., Isidro, G., Martins, A.G. and Boavida, M.G. (1997) Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Cancer Genet. Cytogenet., 96, 134-139.
23. Takita, J., Hayashi, Y., Kohno, T., Yamaguchi, N., Hanada, R., Yamamoto, K. and Yokota, J. (1997) Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res., 57, 907-912.
24. Caren, H., Erichsen, J., Olsson, L., Enerback, C., Sjoberg, R.M., Abrahamsson, J., Kogner, P. and Martinsson, T. (2008) High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics, 9, 353.
25. Van Maerken, T., Rihani, A., Dreidax, D., De Clercq, S., Yigit, N., Marine, J.C., Westermann, F., De Paepe, A., Vandesompele, J. and Speleman, F. (2011) Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol. Cancer Ther., 10, 983-993.
26. Ozenne, P., Eymin, B., Brambilla, E. and Gazzeri, S. (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer, 127, 2239-2247.
27. Esteller, M., Tortola, S., Toyota, M., Capella, G., Peinado, M.A., Baylin, S.B. and Herman, J.G. (2000) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res., 60, 129-133.
28. Hsu, H.S., Wang, Y.C., Tseng, R.C., Chang, J.W., Chen, J.T., Shih, C.M., Chen, C.Y. and Wang, Y.C. (2004) 5′ cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer. Clin. Cancer Res., 10, 4734-4741.
29. Ishida, E., Nakamura, M., Ikuta, M., Shimada, K., Matsuyoshi, S., Kirita, T. and Konishi, N. (2005) Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral. Oncol., 41, 614-622.
30. Kawamoto, K., Enokida, H., Gotanda, T., Kubo, H., Nishiyama, K., Kawahara, M. and Nakagawa, M. (2006) p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem. Biophys. Res. Commun., 339, 790-796.
31. Lee, M., Sup Han, W., Kyoung Kim, O., Hee Sung, S., Sun Cho, M., Lee, S.N. and Koo, H. (2006) Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol. Res. Pract., 202, 415-424.
32. Michalowski, M.B., de Fraipont, F., Plantaz, D., Michelland, S., Combaret, V. and Favrot, M.C. (2008) Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors. Pediatr. Blood Cancer, 50, 29-32.
33. Ochiai, H., Takenobu, H., Nakagawa, A., Yamaguchi, Y., Kimura, M., Ohira, M., Okimoto, Y., Fujimura, Y., Koseki, H., Kohno, Y. et al. (2010) Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene, 29, 2681-2690.
34. Agger, K., Cloos, P.A., Rudkjaer, L., Williams, K., Andersen, G., Christensen, J. and Helin, K. (2009) The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev., 23, 1171-1176.
35. Agherbi, H., Gaussmann-Wenger, A., Verthuy, C., Chasson, L., Serrano, M. and Djabali, M. (2009) Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence. PLoS ONE, 4, e5622.
36. Barradas, M., Anderton, E., Acosta, J.C., Li, S., Banito, A., Rodriguez-Niedenfuhr, M., Maertens, G., Banck, M., Zhou, M.M., Walsh, M.J. et al. (2009) Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev., 23, 1177-1182.
37. Maertens, G.N., El Messaoudi-Aubert, S., Racek, T., Stock, J.K., Nicholls, J., Rodriguez-Niedenfuhr, M., Gil, J. and Peters, G. (2009) Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus. PLoS ONE, 4, e6380.
38. Cui, H., Hu, B., Li, T., Ma, J., Alam, G., Gunning, W.T. and Ding, H.F. (2007) Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am. J. Pathol., 170, 1370-1378.
39. Huang, R., Cheung, N.-K.V., Vider, J., Cheung, I.Y., Gerald, W.L., Tickoo, S.K., Holland, E.C. and Blasberg, R.G. (2011) MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J., 25, 4138-4149.
40. Nowak, K., Kerl, K., Fehr, D., Kramps, C., Gessner, C., Killmer, K., Samans, B., Berwanger, B., Christiansen, H. and Lutz, W. (2006) BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res., 34, 1745-1754.
41. Schulte, J.H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., Ora, I., Pajtler, K., Klein-Hitpass, L., Kuhfittig-Kulle, S. et al. (2009) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res., 69, 2065-2071.
42. Wang, C., Liu, Z., Woo, C.W., Li, Z., Wang, L., Wei, J.S., Marquez, V.E., Bates, S.E., Jin, Q., Khan, J. et al. (2012) EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res., 72, 315-324.
43. Sharma, S.K., Wu, Y., Steinbergs, N., Crowley, M.L., Hanson, A.S., Casero, R.A. and Woster, P.M. (2010) (Bis)urea and (Bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J. Med. Chem., 53, 5197-5212.
44. Wiedemeyer, R., Westermann, F., Wittke, I., Nowock, J. and Schwab, M. (2003) Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene, 22, 401-411.
45. Linggi, B., Muller-Tidow, C., van de Locht, L., Hu, M., Nip, J., Serve, H., Berdel, W.E., van der Reijden, B., Quelle, D.E., Rowley, J.D. et al. (2002) The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med., 8, 743-750.
46. Henrich, K.-O., Bauer, T., Schulte, J., Ehemann, V., Deubzer, H., Gogolin, S., Muth, D., Fischer, M., Benner, A., Koenig, R. et al. (2011) CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res., 71, 3142-3151.
47. Ehemann, V., Hashemi, B., Lange, A. and Otto, H.F. (1999) Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas. Cancer Lett., 138, 101-106.
48. Westermann, F., Henrich, K.-O., Wei, J.S., Lutz, W., Fischer, M., Koenig, R., Wiedemeyer, R., Ehemann, V., Brors, B., Ernestus, K. et al. (2007) High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin. Cancer Res., 13, 4695-4703.
49. Brodeur, G.M., Pritchard, J., Berthold, F., Carlsen, N.L., Castel, V., Castelberry, R.P., De Bernardi, B., Evans, A.E., Favrot, M., Hedborg, F. et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol., 11, 1466-1477.
50. Toedling, J., Sklyar, O. and Huber, W. (2007) Ringo - an R/Bioconductor package for analyzing ChIP-chip readouts. BMC Bioinformatics, 8, 221.
51. Hupe, P., Stransky, N., Thiery, J.P., Radvanyi, F. and Barillot, E. (2004) Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics, 20, 3413-3422.
52. Afanasyeva, E.A., Mestdagh, P., Kumps, C., Vandesompele, J., Ehemann, V., Theissen, J., Fischer, M., Zapatka, M., Brors, B., Savelyeva, L. et al. (2011) MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Diff., 18, 974-984.
53. Spitz, R., Oberthuer, A., Zapatka, M., Brors, B., Hero, B., Ernestus, K., Oestreich, J., Fischer, M., Simon, T. and Berthold, F. (2006) Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer, 45, 1130-1142.
54. Brueckner, L.M., Sagulenko, E., Hess, E.M., Zheglo, D., Blumrich, A., Schwab, M. and Savelyeva, L. (2012) Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats. Hum. Genet., 131, 1345-1359.
55. Mestdagh, P., Fredlund, E., Pattyn, F., Schulte, J.H., Muth, D., Vermeulen, J., Kumps, C., Schlierf, S., De Preter, K., Van Roy, N. et al. (2010) MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene, 29, 1394-1404.